Antiplatelet action of R‐99224, an active metabolite of a novel thienopyridine‐type Gi‐linked P2T antagonist, CS‐747
- 29 January 2001
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 132 (1), 47-54
- https://doi.org/10.1038/sj.bjp.0703761
Abstract
1. CS-747 is a novel thienopyridine-type platelet ADP inhibitor which lacks in vitro activity. This study examined pharmacological profiles of R-99224, a hepatic metabolite of CS-747. 2. R-99224 produced a concentration-dependent inhibition of in vitro platelet aggregation in washed human platelets (0.03 - 1 microg ml(-1)), which was relatively specific to ADP compared to collagen and thrombin. 3. R-99224 (0.1 - 3 microg ml(-1)) also elicited a similar inhibition of ADP-induced aggregation in rat platelets. The inhibition by R-99224 (10 microg ml(-1)) persisted even after platelets were washed three times. Intravenous injection of R-99224 (0.1 - 3 mg kg(-1)) to rats resulted in a dose-dependent inhibition of ex vivo ADP-induced platelet aggregation. 4. R-99224 (0.1 - 100 microM) decreased binding of [(3)H]-2-methylthio-ADP ([(3)H]-2-MeS-ADP), a stable ligand for platelet ADP receptors, to washed human platelets. The inhibition by R-99224 reached a plateau at a concentration of 3 microM (1.4 microg ml(-1)), but complete inhibition was not achieved even at the highest concentration used (100 microM). 5. R-99224 (10 microM) in combination with ARL-66096 (0.3 microM), an ATP analogue-type G(i)-linked P2T receptor antagonist, produced no additional inhibition of [(3)H]-2-MeS-ADP binding. In contrast, [(3)H]-2-MeS-ADP binding was completely abolished by R-99224 (10 microM) in combination with A3P5PS (300 microM), a selective P2Y(1) antagonist, suggesting that R-99224 selectively binds to the G(i)-linked P2T receptor. 6. R-99224 (0.01 - 3 microg ml(-1)) inhibited ADP-induced [(125)I]-fibrinogen binding to human platelets in a concentration-dependent manner. R-99224 (0.1 - 1 microg ml(-1)) also inhibited the ADP-induced decrease in cyclic AMP levels in PGE(1)-stimulated platelets, whereas the agent did not affect ADP (10 microM)-induced Ca(2+) mobilization. 7. These findings suggest that R-99224 is a selective and irreversible antagonist of G(i)-linked P2T receptors and that R-99224 is a responsible molecule for in vivo actions of CS-747.Keywords
This publication has 38 references indexed in Scilit:
- The in vivo pharmacological profile of CS‐747, a novel antiplatelet agent with platelet ADP receptor antagonist propertiesBritish Journal of Pharmacology, 2000
- ADP can induce aggregation of human platelets via both P2Y1 and P2T receptorsBritish Journal of Pharmacology, 2000
- Specific inhibition of ADP‐induced platelet aggregation by clopidogrel in vitroBritish Journal of Pharmacology, 1999
- P2Y1‐receptors in human platelets which are pharmacologically distinct from P2YADP‐receptorsBritish Journal of Pharmacology, 1998
- Functional characterization of platelet ADP receptorsPlatelets, 1998
- ClopidogrelDrugs, 1997
- Activation of Receptor-operated Cation Channels via P2X1 Not P2T Purinoceptors in Human PlateletsPublished by Elsevier BV ,1996
- Receptors for ADP on human blood plateletsTrends in Pharmacological Sciences, 1994
- Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1992
- TiclopidineDrugs, 1987